Foghorn Therapeutics Inc. $FHTX Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC increased its position in shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) by 36.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 406,425 shares of the company’s stock after buying an additional 108,689 shares during the quarter. Renaissance Technologies LLC owned about 0.69% of Foghorn Therapeutics worth $1,943,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Brummer Multi Strategy AB purchased a new position in Foghorn Therapeutics in the fourth quarter worth approximately $25,000. Russell Investments Group Ltd. raised its position in Foghorn Therapeutics by 13,755.0% in the third quarter. Russell Investments Group Ltd. now owns 5,542 shares of the company’s stock valued at $27,000 after purchasing an additional 5,502 shares during the period. BNP Paribas Financial Markets raised its position in Foghorn Therapeutics by 48.0% in the third quarter. BNP Paribas Financial Markets now owns 7,103 shares of the company’s stock valued at $35,000 after purchasing an additional 2,305 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Foghorn Therapeutics by 136.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,213 shares of the company’s stock valued at $43,000 after purchasing an additional 5,323 shares during the last quarter. Finally, Strs Ohio lifted its stake in shares of Foghorn Therapeutics by 120.5% in the 4th quarter. Strs Ohio now owns 8,600 shares of the company’s stock valued at $46,000 after purchasing an additional 4,700 shares during the last quarter. 61.55% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Foghorn Therapeutics

Here are the key news stories impacting Foghorn Therapeutics this week:

• Positive Sentiment: Analysts’ average price target implies approximately 88.5% potential upside for FHTX. Although price targets are not always reliable, the expectation of meaningful appreciation may be supporting investor interest. Wall Street Analysts Believe Foghorn Therapeutics Could Rally 88.47%
• Positive Sentiment: HC Wainwright raised its Foghorn Therapeutics FY2026 EPS forecast to a loss of $0.91 per share from a projected loss of $1.06, and improved its FY2027 estimate to a loss of $0.84 from $0.90. While the company remains unprofitable, these revisions suggest somewhat better expected results in the next two years.
• Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior report, with a zero-day days-to-cover ratio. Because the data appears incomplete or anomalous, it provides little actionable information about short-selling pressure.
• Negative Sentiment: HC Wainwright lowered its Q3 2026 EPS forecast to a loss of $0.29 from $0.28 and its Q4 forecast to a loss of $0.23 from $0.21, indicating weaker expected near-term profitability.
• Negative Sentiment: The firm also reduced longer-term EPS forecasts, including FY2028 to a loss of $0.84 from $0.57, FY2029 to a loss of $0.84 from $0.04, and FY2030 to a loss of $0.72 from previously expected earnings of $0.36. These revisions point to a slower path toward profitability.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on FHTX. Wall Street Zen upgraded Foghorn Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Foghorn Therapeutics in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $11.43.

Foghorn Therapeutics Stock Up 5.6%

NASDAQ:FHTX opened at $6.59 on Wednesday. The stock’s fifty day moving average is $4.83 and its two-hundred day moving average is $4.97. Foghorn Therapeutics Inc. has a 52 week low of $3.27 and a 52 week high of $6.95. The stock has a market capitalization of $391.31 million, a price-to-earnings ratio of -6.72 and a beta of 2.89.

Foghorn Therapeutics (NASDAQ:FHTX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.14. The firm had revenue of $16.10 million for the quarter, compared to analysts’ expectations of $6.80 million. On average, sell-side analysts expect that Foghorn Therapeutics Inc. will post -0.91 EPS for the current fiscal year.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine.

The company’s lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations.